Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways

DNA damaging therapies can spur the formation of therapy-related cancers, due to mis-repair of lesions they create in non-cancerous cells. This risk may be amplified in patients with impaired DNA damage responses. We disabled key DNA damage response pathways using genetic and pharmacological approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, Mark A., Hawkins, Christine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158240/
https://www.ncbi.nlm.nih.gov/pubmed/30258062
http://dx.doi.org/10.1038/s41598-018-32517-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158240/
https://www.ncbi.nlm.nih.gov/pubmed/30258062
http://dx.doi.org/10.1038/s41598-018-32517-9

Ejemplares similares